CLIA Kit for Bone Morphogenetic Protein 2 (BMP2) Homo sapiens (Human) Sandwich CLIA

BMP2A; BMP-2A; Hemochromatosis Modifier

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Bone Morphogenetic Protein 2 (BMP2) Packages (Simulation)
  • CLIA Kit for Bone Morphogenetic Protein 2 (BMP2) Packages (Simulation)
  • CLIA Kit for Bone Morphogenetic Protein 2 (BMP2) Results demonstration
  • SCA013Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Bone Morphogenetic Protein 2 (BMP2) and the recovery rates were calculated by comparing the measured value to the expected amount of Bone Morphogenetic Protein 2 (BMP2) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-102 83
EDTA plasma(n=5) 79-91 87
heparin plasma(n=5) 91-104 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Bone Morphogenetic Protein 2 (BMP2) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Bone Morphogenetic Protein 2 (BMP2) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Bone Morphogenetic Protein 2 (BMP2) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-99% 78-92% 89-99% 87-96%
EDTA plasma(n=5) 78-99% 86-94% 84-101% 94-105%
heparin plasma(n=5) 79-93% 85-94% 81-91% 91-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Bone Morphogenetic Protein 2 (BMP2)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Bone Morphogenetic Protein 2 (BMP2). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Bone Morphogenetic Protein 2 (BMP2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Bone Morphogenetic Protein 2 (BMP2) level in the sample or standard.;

Citations

  • Chronic exposure to low concentrations of strontium 90 affects bone physiology but not the hematopoietic system in miceWiley: Source
  • A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic ApproachesPlosone: Source
  • Effect of transplantation of BMP-2-induced bone marrow mesenchymal stem cells on myocardial infarction of rats after reperfusionSource
  • PDGF-AA promotes osteogenic differentiation and migration of mesenchymal stem cell by down-regulating PDGFRα and derepressing BMP-Smad1/5/8 signalingPubmed:25470749
  • Negative effect of serotonin–norepinephrine reuptake inhibitor therapy on rat bone tissue after orchidectomyPubMed: 25934570
  • Effect of Mirtazapine on Rat Bone Tissue after OrchidectomyPubMed: 25871861
  • Titanium with Nanotopography Induces Osteoblast Differentiation by Regulating Endogenous Bone Morphogenetic Protein Expression and Signaling PathwayPubMed: 26681207
  • Sustained dual release of placental growth factor-2 and bone morphogenic protein-2 from heparin-based nanocomplexes for direct osteogenesisPubmed:27042064
  • EFFECTS OF FLUORIDE ON THE EXPRESSION OF BMP-2 AND SMAD1 IN RAT OSTEOBLASTS IN VITROfiles:p013-022
  • Unveiling the interactions among BMPR-2, ALK-1 and 5-HTT genes in the pathophysiology of HAPEPubmed:27196063
  • Extracellular Matrix Powder from Cultured Cartilage-Like Tissue as Cell Carriers for Cartilage RepairDOI:10.1039/C7TB00640C
  • 3D- Printed Poly(ε-caprolactone) Scaffold Integrated with Cell-laden Chitosan Hydrogels for Bone Tissue Engineering.pubmed:29042614
  • Demineralized dentin and enamel matrices as suitable substrates for bone regenerationpubmed:28731486
  • Peroxisome proliferator‐activated receptor γ plays dual roles on experimental periodontitis in ratsPubmed:29574908
  • Effects of Amlodipine on Bone Metabolism in Orchidectomised Spontaneously Hypertensive RatsPubmed:29898457
  • BMP-2 and type I collagen preservation in human deciduous teeth after demineralizationPubmed:30045659
  • Enhanced osteogenic differentiation of MC3T3-E1 on rhBMP-2 immobilized titanium surface through polymer-mediated electrostatic interaction
  • Injectable hydrogels from enzyme-catalyzed crosslinking as BMSCs-laden scaffold for bone repair and regeneration
  • Development of CaCO 3 microsphere-based composite hydrogel for dual delivery of growth factor and Ca to enhance bone regeneration
  • The dose-time effects of fluoride on the expression and DNA methylation level of the promoter region of BMP-2 and BMP-7 in ratsPubmed: 32004919
  • Biofabrication and application of decellularized bone extracellular matrix for effective bone regeneration
  • Synergistic Effect of Platelet-rich Fibrin Releasate and Bone Marrow Stem Cells in Preventing Bone Loss in Ovariectomized Mouse
  • New design to remove leukocytes from platelet-rich plasma (PRP) based on cell dimension rather than density33842739
  • Osteogenic and Angiogenic Potency of VEGF165-Transfected Canine Bone Marrow Mesenchymal Cells Combined with Coral Hydroxyapatite in Vitro34302695
  • The WNT/β-catenin signalling pathway induces chondrocyte apoptosis in the cartilage injury caused by T-2 toxin in rats34742779
  • Polydopamine-Coated Poly(l-lactide) Nanofibers with Controlled Release of VEGF and BMP-2 as a Regenerative Periosteum34472855
  • Efficacy of Total flavonoids of Rhizoma drynariae on the Blood Vessels and the Growth Quality of Bone Graft in the Induced MembranePubmed:35278899

Recommend products